No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Pluri Shares Are Trading Higher After the Company Announced FDA Approval for Mesoblast.
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
Pluri Assesses Readiness For Mass Production Of PLX-R18 For Acute Radiation Syndrome
Pluri Inc | 10-Q: Q1 2025 Earnings Report
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn Phase 3b Trial Manufacturing
No Data